20. december 2024 · proinvestor.com
Zealand Pharma - Company announcement - FDA/glepaglutide
EASE-1 (NCT03690206) is a randomized, double-blind Phase 3 trial that enrolled a total of 106 SBS patients with intestinal failure who were dependent on parenteral support for at least three days per week.
Læs artikel